|
1
|
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
|
Lancet
|
2000
|
12.56
|
|
2
|
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
|
J Clin Oncol
|
1997
|
5.89
|
|
3
|
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.
|
Br J Cancer
|
2001
|
5.36
|
|
4
|
Insulin biosynthesis: evidence for a precursor.
|
Science
|
1967
|
5.05
|
|
5
|
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
|
J Natl Cancer Inst
|
1998
|
4.65
|
|
6
|
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
|
J Clin Oncol
|
2002
|
3.98
|
|
7
|
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
|
Ann Oncol
|
2002
|
3.91
|
|
8
|
Biotechnology awareness study, Part 1: Where scientists get their information.
|
Bull Med Libr Assoc
|
1991
|
3.85
|
|
9
|
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
|
Eur J Cancer
|
1998
|
3.36
|
|
10
|
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
|
Ann Oncol
|
2009
|
3.33
|
|
11
|
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
|
Ann Oncol
|
1997
|
2.71
|
|
12
|
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
|
Ann Oncol
|
2009
|
2.47
|
|
13
|
Radiographic interpretation by nurse practitioners in a minor injuries unit.
|
J Accid Emerg Med
|
1996
|
2.44
|
|
14
|
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
|
Ann Oncol
|
2005
|
2.41
|
|
15
|
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2010
|
2.31
|
|
16
|
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
|
J Clin Oncol
|
2000
|
2.29
|
|
17
|
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
|
Lancet
|
1991
|
2.26
|
|
18
|
From quantity to quality: the central cardiac audit database project.
|
Heart
|
1999
|
2.23
|
|
19
|
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
|
J Clin Oncol
|
2000
|
2.19
|
|
20
|
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
|
Ann Oncol
|
2008
|
2.14
|
|
21
|
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events.
|
J Virol
|
2001
|
2.13
|
|
22
|
Management of carcinomas of the upper gastrointestinal tract.
|
BMJ
|
1994
|
2.12
|
|
23
|
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2000
|
2.12
|
|
24
|
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
|
Eur J Cancer
|
1996
|
2.11
|
|
25
|
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
|
Lancet
|
1987
|
2.09
|
|
26
|
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
|
J Clin Oncol
|
1996
|
2.08
|
|
27
|
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.
|
J Clin Oncol
|
1995
|
2.08
|
|
28
|
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
|
Ann Oncol
|
1994
|
2.02
|
|
29
|
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study.
|
Eur Heart J
|
1995
|
1.97
|
|
30
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
Br J Cancer
|
2004
|
1.94
|
|
31
|
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
|
Br J Cancer
|
2005
|
1.81
|
|
32
|
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
|
Br J Cancer
|
1999
|
1.80
|
|
33
|
Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2013
|
1.68
|
|
34
|
MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?
|
Br J Cancer
|
2006
|
1.68
|
|
35
|
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).
|
Eur J Cancer
|
2002
|
1.66
|
|
36
|
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
|
Ann Oncol
|
2012
|
1.65
|
|
37
|
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.
|
Gut
|
2003
|
1.61
|
|
38
|
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
|
J Clin Oncol
|
1999
|
1.59
|
|
39
|
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.
|
Br J Cancer
|
2007
|
1.58
|
|
40
|
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group.
|
Tumori
|
1998
|
1.54
|
|
41
|
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
|
Ann Oncol
|
2011
|
1.51
|
|
42
|
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
|
Br J Cancer
|
2008
|
1.50
|
|
43
|
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
|
Ann Oncol
|
2004
|
1.49
|
|
44
|
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
|
Br J Cancer
|
2005
|
1.47
|
|
45
|
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
|
J Clin Oncol
|
2004
|
1.46
|
|
46
|
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.
|
J Am Coll Cardiol
|
1994
|
1.45
|
|
47
|
Detecting t(14;18) in paraffin-embedded lymphoma tissue.
|
Lancet
|
1989
|
1.45
|
|
48
|
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
|
Eur J Cancer
|
2003
|
1.45
|
|
49
|
Baseline quality of life predicts survival in patients with advanced colorectal cancer.
|
Eur J Cancer
|
2002
|
1.45
|
|
50
|
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
|
Ann Oncol
|
2007
|
1.44
|
|
51
|
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
|
Eur J Cancer
|
1998
|
1.44
|
|
52
|
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity.
|
J Clin Oncol
|
1995
|
1.43
|
|
53
|
Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease.
|
Eur Heart J
|
1995
|
1.43
|
|
54
|
Adjuvant therapy in pancreatic cancer: historical and current perspectives.
|
Ann Oncol
|
2003
|
1.42
|
|
55
|
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
|
Ann Oncol
|
2005
|
1.41
|
|
56
|
Myeloma and benign intracranial hypertension.
|
BMJ
|
1992
|
1.41
|
|
57
|
Treatment in advanced colorectal cancer: what, when and how?
|
Br J Cancer
|
2009
|
1.40
|
|
58
|
Prevention and therapy of serous otitis media by oral decongestant: a double-blind study in pediatric practice.
|
Pediatrics
|
1978
|
1.39
|
|
59
|
Prothrombin mRNA is expressed by cells of the nervous system.
|
Neuron
|
1991
|
1.38
|
|
60
|
Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease.
|
Proc Natl Acad Sci U S A
|
1991
|
1.37
|
|
61
|
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
|
Ann Oncol
|
2004
|
1.34
|
|
62
|
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
|
Br J Cancer
|
2005
|
1.34
|
|
63
|
Chest pain in women: clinical, investigative, and prognostic features.
|
BMJ
|
1994
|
1.32
|
|
64
|
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
|
Eur J Cancer
|
1995
|
1.31
|
|
65
|
Adjuvant therapy in colon cancer--what, when and how?
|
Ann Oncol
|
2006
|
1.30
|
|
66
|
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma.
|
Lancet
|
1997
|
1.30
|
|
67
|
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
|
Br J Cancer
|
1999
|
1.27
|
|
68
|
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
|
Blood
|
1993
|
1.27
|
|
69
|
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
|
Ann Oncol
|
2009
|
1.26
|
|
70
|
Phase I immunotoxin trial in patients with B-cell lymphoma.
|
Cancer Res
|
1991
|
1.26
|
|
71
|
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
|
Br Med J (Clin Res Ed)
|
1985
|
1.25
|
|
72
|
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2009
|
1.25
|
|
73
|
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
|
Br J Cancer
|
2009
|
1.25
|
|
74
|
Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications?
|
Clin Oncol (R Coll Radiol)
|
2004
|
1.23
|
|
75
|
Low energy catheter ablation of a posteroseptal accessory pathway associated with a diverticulum of the coronary sinus.
|
Pacing Clin Electrophysiol
|
1991
|
1.23
|
|
76
|
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
|
Cancer Res
|
1986
|
1.19
|
|
77
|
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
|
Ann Oncol
|
2008
|
1.18
|
|
78
|
Long-term follow-up study of survival and recurrence rates following myocardial infarction in exercising and control subjects.
|
Circulation
|
1972
|
1.18
|
|
79
|
Chemotherapy of carcinoma of the stomach.
|
Cancer Treat Rev
|
1993
|
1.16
|
|
80
|
Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination.
|
Eur Radiol
|
2008
|
1.16
|
|
81
|
Transvenous ablation of atrioventricular conduction with a low energy power source.
|
Br Heart J
|
1989
|
1.15
|
|
82
|
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
|
Br J Cancer
|
1998
|
1.15
|
|
83
|
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
|
J Clin Oncol
|
1996
|
1.14
|
|
84
|
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
|
J Clin Oncol
|
1998
|
1.14
|
|
85
|
Comparative genome sequence analysis of the Bpa/Str region in mouse and Man.
|
Genome Res
|
2000
|
1.13
|
|
86
|
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
|
Ann Oncol
|
2013
|
1.13
|
|
87
|
The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.
|
Br J Cancer
|
1993
|
1.13
|
|
88
|
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
|
Eur J Cancer
|
2006
|
1.12
|
|
89
|
High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
|
J Clin Oncol
|
1999
|
1.12
|
|
90
|
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.
|
J Clin Oncol
|
2001
|
1.12
|
|
91
|
Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis.
|
Lancet
|
1989
|
1.11
|
|
92
|
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
|
Br J Cancer
|
2005
|
1.11
|
|
93
|
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
|
Ann Oncol
|
2011
|
1.11
|
|
94
|
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
|
Br J Cancer
|
2003
|
1.10
|
|
95
|
Circadian variation of total ischaemic burden and its alteration with anti-anginal agents.
|
Lancet
|
1988
|
1.10
|
|
96
|
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.
|
Br J Cancer
|
2002
|
1.09
|
|
97
|
Right phrenic nerve palsy as a complication of indwelling central venous catheters.
|
Thorax
|
1997
|
1.08
|
|
98
|
Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha.
|
Ann Oncol
|
1996
|
1.08
|
|
99
|
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
|
Eur J Cancer
|
1999
|
1.07
|
|
100
|
Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients.
|
Br J Cancer
|
2003
|
1.05
|
|
101
|
Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.
|
Br J Cancer
|
1991
|
1.05
|
|
102
|
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
|
Br J Cancer
|
1997
|
1.05
|
|
103
|
Continuous ambulatory pulmonary artery pressure monitoring. A new method using a transducer tipped catheter and a simple recording system.
|
Br Heart J
|
1986
|
1.04
|
|
104
|
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
|
Ann Oncol
|
2010
|
1.04
|
|
105
|
Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
|
Br J Cancer
|
1997
|
1.04
|
|
106
|
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
|
Br J Surg
|
1984
|
1.04
|
|
107
|
Mapping full-length porcine endogenous retroviruses in a large white pig.
|
J Virol
|
2001
|
1.04
|
|
108
|
Current options in the management of gastrointestinal cancer.
|
Ann Oncol
|
1995
|
1.03
|
|
109
|
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection.
|
Br J Cancer
|
2012
|
1.03
|
|
110
|
Fertilization and pregnancy using intentionally cryopreserved testicular tissue as the sperm source for intracytoplasmic sperm injection in 10 men with non-obstructive azoospermia.
|
Hum Reprod
|
1997
|
1.02
|
|
111
|
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
|
J Clin Oncol
|
1995
|
1.02
|
|
112
|
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
|
Ann Oncol
|
2008
|
1.01
|
|
113
|
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
|
Ann Oncol
|
2012
|
1.01
|
|
114
|
Functional and structural changes of the human proximal small intestine after cytotoxic therapy.
|
J Clin Pathol
|
1985
|
1.01
|
|
115
|
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
|
J Clin Oncol
|
1996
|
1.00
|
|
116
|
Adenine nucleotide binding sites on beef heart F1 ATPase: photoaffinity labeling of beta-subunit Tyr-368 at a noncatalytic site and beta Tyr-345 at a catalytic site.
|
Proc Natl Acad Sci U S A
|
1987
|
1.00
|
|
117
|
A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy.
|
Eur J Cancer
|
1997
|
1.00
|
|
118
|
Systemic treatment of colorectal cancer.
|
Eur J Cancer
|
2002
|
1.00
|
|
119
|
K-ras mutations in patients with early colorectal cancers.
|
Gut
|
1997
|
0.99
|
|
120
|
AIDS: counting the cost.
|
Br Med J (Clin Res Ed)
|
1987
|
0.99
|
|
121
|
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
|
Ann Oncol
|
1993
|
0.99
|
|
122
|
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.
|
Br J Cancer
|
2007
|
0.99
|
|
123
|
The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.
|
Eur J Cancer
|
1996
|
0.98
|
|
124
|
The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.98
|
|
125
|
The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2003
|
0.98
|
|
126
|
Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
|
Eur J Cancer Clin Oncol
|
1986
|
0.98
|
|
127
|
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
|
Cancer
|
1996
|
0.98
|
|
128
|
The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
|
Ann Oncol
|
1995
|
0.98
|
|
129
|
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
|
Ann Oncol
|
2002
|
0.98
|
|
130
|
Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs.
|
Br Med J (Clin Res Ed)
|
1985
|
0.98
|
|
131
|
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
|
Ann Oncol
|
2004
|
0.97
|
|
132
|
Dispersion of monophasic action potential duration: demonstrable in humans after premature ventricular extrastimulation but not in steady state.
|
J Am Coll Cardiol
|
1992
|
0.97
|
|
133
|
Myocyte reactions at the borders of injured and healing rat myocardium.
|
Lab Invest
|
1988
|
0.97
|
|
134
|
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
|
Br J Cancer
|
2006
|
0.96
|
|
135
|
Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.
|
Ann Oncol
|
2010
|
0.96
|
|
136
|
Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.
|
Cancer Res
|
1994
|
0.96
|
|
137
|
Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.
|
J Clin Invest
|
1995
|
0.96
|
|
138
|
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
|
Br J Cancer
|
2004
|
0.95
|
|
139
|
The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
|
Ann Oncol
|
2006
|
0.95
|
|
140
|
Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
|
Lancet
|
1994
|
0.94
|
|
141
|
Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation.
|
Support Care Cancer
|
2006
|
0.94
|
|
142
|
The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT).
|
Am J Pathol
|
1989
|
0.94
|
|
143
|
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.
|
Br J Cancer
|
2003
|
0.94
|
|
144
|
Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.
|
Br J Cancer
|
1995
|
0.94
|
|
145
|
A method for measuring team skills.
|
Ergonomics
|
2000
|
0.93
|
|
146
|
Prevention and treatment of serous otitis media with an oral antihistamine. A double-blind study in pediatric practice.
|
Clin Pediatr (Phila)
|
1980
|
0.93
|
|
147
|
Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation.
|
J Clin Invest
|
1996
|
0.93
|
|
148
|
A large outbreak of Salmonella enteritidis phage type 4 associated with eggs from overseas.
|
Epidemiol Infect
|
1989
|
0.93
|
|
149
|
Comparison of long-term survival outcome of operative vs nonoperative management of recurrent rectal cancer.
|
Colorectal Dis
|
2013
|
0.93
|
|
150
|
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
|
Ann Oncol
|
2000
|
0.92
|
|
151
|
Unpredictable zero drift in intravascular micromanometer tipped catheters during long term pulmonary artery pressure recording: implications for catheter design.
|
Cardiovasc Res
|
1989
|
0.92
|
|
152
|
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
|
Br J Cancer
|
1995
|
0.92
|
|
153
|
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.
|
Cancer Chemother Pharmacol
|
1985
|
0.92
|
|
154
|
A new low energy power source for catheter ablation.
|
Pacing Clin Electrophysiol
|
1986
|
0.92
|
|
155
|
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
|
Br J Haematol
|
2000
|
0.91
|
|
156
|
Use of Leu M1 and antiepithelial membrane antigen monoclonal antibodies for diagnosing Hodgkin's disease.
|
J Clin Pathol
|
1986
|
0.91
|
|
157
|
Survival from cancer of the pancreas in England and Wales up to 2001.
|
Br J Cancer
|
2008
|
0.91
|
|
158
|
Pulmonary infiltrates--diagnostic problems in lymphoma.
|
Postgrad Med J
|
1989
|
0.91
|
|
159
|
An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
|
Br J Haematol
|
2001
|
0.91
|
|
160
|
Onycholysis associated with cytotoxic drugs.
|
Br Med J (Clin Res Ed)
|
1985
|
0.91
|
|
161
|
Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease.
|
Blood
|
1992
|
0.91
|
|
162
|
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
|
Blood
|
2001
|
0.91
|
|
163
|
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
|
Br J Cancer
|
2003
|
0.90
|
|
164
|
Medical management of advanced gastric cancer.
|
Cancer Treat Rev
|
1998
|
0.90
|
|
165
|
Diurnal variation of pulmonary artery pressure in chronic heart failure.
|
Br Heart J
|
1989
|
0.90
|
|
166
|
Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret.
|
Br J Cancer
|
1990
|
0.90
|
|
167
|
Catheter ablation without fulguration: design and performance of a new system.
|
Pacing Clin Electrophysiol
|
1989
|
0.89
|
|
168
|
Human Bcl-2 antisense therapy for lymphomas.
|
Biochim Biophys Acta
|
1999
|
0.89
|
|
169
|
Meningeal carcinomatosis from transitional cell carcinoma of the bladder.
|
Cancer
|
1993
|
0.89
|
|
170
|
Survival from cancer of the oesophagus in England and Wales up to 2001.
|
Br J Cancer
|
2008
|
0.89
|
|
171
|
A clinical nomogram for predicting long-term survival in advanced colorectal cancer.
|
Eur J Cancer
|
2000
|
0.88
|
|
172
|
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
|
Ann Oncol
|
2009
|
0.88
|
|
173
|
CT of calcified liver metastases in colorectal carcinoma.
|
Clin Radiol
|
1998
|
0.88
|
|
174
|
Steroid biosynthesis in vitro by tissue from a granulosa cell multilocular cystadenoma.
|
J Endocrinol
|
1966
|
0.88
|
|
175
|
Low energy catheter ablation of right ventricular outflow tract tachycardia.
|
Br Heart J
|
1991
|
0.88
|
|
176
|
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
|
Br J Cancer
|
2004
|
0.88
|
|
177
|
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
|
Ann Oncol
|
2003
|
0.88
|
|
178
|
Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
|
Int J Clin Pract
|
2004
|
0.88
|
|
179
|
The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis.
|
Br J Radiol
|
2013
|
0.88
|
|
180
|
Acute retinal pigment epitheliitis and hepatitis C.
|
Am J Ophthalmol
|
1994
|
0.88
|
|
181
|
Effects of physical training on cardiovascular function following myocardial infarction.
|
J Appl Physiol Respir Environ Exerc Physiol
|
1979
|
0.88
|
|
182
|
Heart rate and blood pressure consequences of an afternoon SIESTA (Snooze-Induced Excitation of Sympathetic Triggered Activity).
|
Am J Cardiol
|
1993
|
0.87
|
|
183
|
Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes.
|
Br J Radiol
|
2004
|
0.87
|
|
184
|
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
|
Ann Oncol
|
2013
|
0.87
|
|
185
|
Diurnal variation in left ventricular function: a study of patients with myocardial ischaemia, syndrome X, and of normal controls.
|
Br Heart J
|
1987
|
0.87
|
|
186
|
High-dose busulfan in patients with myeloma.
|
J Clin Oncol
|
1992
|
0.87
|
|
187
|
Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease.
|
Br J Cancer
|
1997
|
0.87
|
|
188
|
Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial.
|
J Hum Nutr Diet
|
2011
|
0.87
|
|
189
|
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
|
Ann Oncol
|
2009
|
0.86
|
|
190
|
Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer.
|
Br J Cancer
|
1999
|
0.86
|
|
191
|
Comparative assessment of small intestinal and colonic permeability in HIV-infected homosexual men.
|
AIDS
|
1995
|
0.86
|
|
192
|
Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
|
J Clin Oncol
|
1995
|
0.86
|
|
193
|
A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
|
Ann Oncol
|
2011
|
0.86
|
|
194
|
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
|
Br J Cancer
|
1997
|
0.86
|
|
195
|
Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas.
|
Br Med J (Clin Res Ed)
|
1985
|
0.86
|
|
196
|
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
|
Br J Cancer
|
2008
|
0.86
|
|
197
|
Progression of pseudovitelliform macular dystrophy.
|
Arch Ophthalmol
|
1984
|
0.86
|
|
198
|
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
|
Br J Cancer
|
2009
|
0.85
|
|
199
|
The retinal depression sign in diabetic retinopathy.
|
Graefes Arch Clin Exp Ophthalmol
|
1995
|
0.85
|
|
200
|
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
|
Br J Cancer
|
2000
|
0.85
|
|
201
|
The rights of woman.
|
Br Heart J
|
1994
|
0.85
|
|
202
|
Basal lamina of rat myocardium. Its fate after death of cardiac myocytes.
|
Lab Invest
|
1988
|
0.85
|
|
203
|
Endothelial cell and platelet binding sites for thrombin.
|
Ann N Y Acad Sci
|
1981
|
0.85
|
|
204
|
A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
|
Br J Haematol
|
1997
|
0.85
|
|
205
|
Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality.
|
J Hosp Infect
|
2006
|
0.85
|
|
206
|
Chemotherapy in advanced gastric cancer.
|
Cancer Treat Rep
|
1985
|
0.85
|
|
207
|
Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience.
|
Eur J Cancer
|
1999
|
0.85
|
|
208
|
Markers, markers everywhere..... Prognosis in colorectal cancer--time for a new approach.
|
J Clin Oncol
|
2001
|
0.85
|
|
209
|
The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies.
|
Anticancer Drugs
|
1998
|
0.85
|
|
210
|
Raltitrexed: current clinical status and future directions.
|
Ann Oncol
|
2002
|
0.85
|
|
211
|
Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.
|
Bone Marrow Transplant
|
1993
|
0.85
|
|
212
|
Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
|
Bone Marrow Transplant
|
1997
|
0.85
|
|
213
|
A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
|
Eur J Cancer Clin Oncol
|
1983
|
0.84
|
|
214
|
Targeted drug therapies and cancer.
|
Recent Results Cancer Res
|
2011
|
0.84
|
|
215
|
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
|
Ann Oncol
|
2011
|
0.84
|
|
216
|
Long-term follow up of patients treated with a software based antitachycardia pacemaker.
|
Br Heart J
|
1993
|
0.84
|
|
217
|
Different central and peripheral responses to leptin in rhesus monkeys: brain transport may be limited.
|
J Clin Endocrinol Metab
|
1998
|
0.84
|
|
218
|
The changing face of chemotherapy in colorectal cancer.
|
Br J Cancer
|
2001
|
0.84
|
|
219
|
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
|
Ann Oncol
|
1995
|
0.84
|
|
220
|
Does rectal cancer height influence the oncological outcome?
|
Colorectal Dis
|
2014
|
0.84
|
|
221
|
Renal tubular acidosis due to oxaliplatin.
|
Ann Oncol
|
2007
|
0.83
|
|
222
|
Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.
|
Stem Cells
|
1995
|
0.83
|
|
223
|
Clarifying the TNM staging of rectal cancer in the context of modern imaging and neo-adjuvant treatment: 'y''u' and 'p' need 'mr' and 'ct'.
|
Colorectal Dis
|
2007
|
0.83
|
|
224
|
Cervical hernia of the lung associated with the cri du chat syndrome.
|
Am J Dis Child
|
1969
|
0.83
|
|
225
|
New approaches to the treatment of gastro-intestinal cancer.
|
Digestion
|
1997
|
0.83
|
|
226
|
An animal model of visual loss from orbital hemorrhage.
|
Ophthal Plast Reconstr Surg
|
1994
|
0.83
|
|
227
|
Presence of mature sperm in testicular parenchyma of men with nonobstructive azoospermia: prevalence and predictive factors.
|
Urology
|
1997
|
0.83
|
|
228
|
High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
|
Br J Cancer
|
1996
|
0.83
|
|
229
|
Definition of disease-free survival: this is my truth-show me yours.
|
Ann Oncol
|
2005
|
0.83
|
|
230
|
Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
|
Br J Haematol
|
2005
|
0.83
|
|
231
|
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.
|
Ann Oncol
|
2005
|
0.82
|
|
232
|
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
|
Med Oncol Tumor Pharmacother
|
1986
|
0.82
|
|
233
|
Chemotherapy for advanced pancreatic cancer--some light at the end of the tunnel?
|
Ann Oncol
|
1997
|
0.82
|
|
234
|
5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma.
|
Cancer Chemother Pharmacol
|
2005
|
0.82
|
|
235
|
Binding change mechanism for ATP synthesis by oxidative phosphorylation and photophosphorylation.
|
Curr Top Cell Regul
|
1984
|
0.82
|
|
236
|
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
|
Cancer Chemother Pharmacol
|
2008
|
0.82
|
|
237
|
Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age?
|
Eur J Cancer
|
1999
|
0.82
|
|
238
|
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
|
Br J Cancer
|
2005
|
0.82
|
|
239
|
Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
|
Acta Haematol
|
2009
|
0.82
|
|
240
|
Improving decision-making and documentation relating to do not attempt resuscitation orders.
|
Resuscitation
|
2003
|
0.82
|
|
241
|
Regenerated hair cells in the European starling: are they more resistant to kanamycin ototoxicity than original hair cells?
|
Hear Res
|
1995
|
0.82
|
|
242
|
Myocardial hydroxyproline reduced by early administration of methylprednisolone or ibuprofen to rabbits with radiation-induced heart disease.
|
Circulation
|
1982
|
0.82
|
|
243
|
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
|
Br J Cancer
|
2012
|
0.82
|
|
244
|
Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.
|
Br J Cancer
|
2013
|
0.81
|
|
245
|
Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer.
|
Oncology
|
2010
|
0.81
|
|
246
|
The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
|
Br J Cancer
|
2007
|
0.81
|
|
247
|
Kinetics of paraprotein clearance after autografting for multiple myeloma.
|
Bone Marrow Transplant
|
1995
|
0.81
|
|
248
|
Electrical restitution in the endocardium of the intact human right ventricle.
|
Br Heart J
|
1992
|
0.81
|
|
249
|
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
|
Br J Cancer
|
2006
|
0.81
|
|
250
|
Multiple myeloma: appearance at MR imaging.
|
Radiology
|
1992
|
0.81
|
|
251
|
Access to cardiac catheterisation. Influenced by deprivation, not sex.
|
BMJ
|
1994
|
0.81
|
|
252
|
Gastrointestinal cancer: recent developments in medical oncology.
|
Eur J Surg Oncol
|
2005
|
0.81
|
|
253
|
Development of a disease specific questionnaire to supplement a generic tool for QoL in colorectal cancer.
|
Psychooncology
|
2003
|
0.81
|
|
254
|
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
|
Ann Oncol
|
2007
|
0.81
|
|
255
|
Expression of human platelet glycoprotein Ib beta in insect cells.
|
Thromb Res
|
1996
|
0.81
|
|
256
|
The failure of conventional methods to promote spontaneous transpyloric feeding tube passage and the safety of intragastric feeding in the critically ill ventilated patient.
|
Surg Gynecol Obstet
|
1993
|
0.80
|
|
257
|
Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient.
|
Bone Marrow Transplant
|
2001
|
0.80
|
|
258
|
Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group.
|
Clin Oncol (R Coll Radiol)
|
1992
|
0.80
|
|
259
|
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
|
Br J Cancer
|
2003
|
0.80
|
|
260
|
Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours.
|
Br J Radiol
|
2002
|
0.80
|
|
261
|
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.
|
Ann Oncol
|
2006
|
0.80
|
|
262
|
Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.
|
Br J Cancer
|
2013
|
0.80
|
|
263
|
T-cell lymphoblastic lymphoma of the uterus complicated by Chlamydia trachomatis pneumonia.
|
Postgrad Med J
|
1986
|
0.80
|
|
264
|
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.
|
Gut
|
2001
|
0.80
|
|
265
|
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
|
Br J Cancer
|
1997
|
0.80
|
|
266
|
Measuring the impact of health interventions: a review of available instruments.
|
Eff Health Care
|
1985
|
0.80
|
|
267
|
Optic neuropathy following simulation of orbital hemorrhage in the nonhuman primate.
|
Ophthal Plast Reconstr Surg
|
1996
|
0.80
|
|
268
|
Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides.
|
Mol Cancer Ther
|
2001
|
0.79
|
|
269
|
cis-Platinum(II)diamminodichloride-induced mutagenesis in E. coli K12: crowding depression of mutagenesis.
|
Mutat Res
|
1981
|
0.79
|
|
270
|
Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.
|
Leuk Lymphoma
|
1996
|
0.79
|
|
271
|
Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.
|
J Clin Oncol
|
1993
|
0.79
|
|
272
|
Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.
|
Br J Cancer
|
1991
|
0.79
|
|
273
|
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
|
Ann Oncol
|
2004
|
0.79
|
|
274
|
Cardiovascular effects of chloroethylclonidine, an irreversible alpha 1B-adrenoceptor antagonist, in the unanesthetized rat: a pharmacological analysis in vivo and in vitro.
|
J Pharmacol Exp Ther
|
1993
|
0.79
|
|
275
|
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
|
Ann Oncol
|
1997
|
0.79
|
|
276
|
Multimodality treatment for localized gastro-oesophageal cancer.
|
Ann Oncol
|
2010
|
0.79
|
|
277
|
Investigating lymphadenopathy--report on the first 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital.
|
Postgrad Med J
|
2000
|
0.79
|
|
278
|
Thymidine phosphorylase (TP) activation: convenience through innovation.
|
Oncologist
|
2001
|
0.79
|
|
279
|
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
|
Br J Cancer
|
2010
|
0.79
|
|
280
|
Physiological responses of bacteria to cytochalasin A: effects on growth, transport, and enzyme induction.
|
J Bacteriol
|
1979
|
0.78
|
|
281
|
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
|
Br J Cancer
|
1990
|
0.78
|
|
282
|
Micrometastases: are they clinically significant disease?
|
Gut
|
1997
|
0.78
|
|
283
|
Curing gastric cancer--hone the scalpel with magic?
|
Br J Cancer
|
1996
|
0.78
|
|
284
|
The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum.
|
Br J Clin Pharmacol
|
1985
|
0.78
|
|
285
|
Calcipotriol and regression in T-cell lymphoma of skin.
|
Lancet
|
1993
|
0.78
|
|
286
|
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
|
Hematol Oncol
|
1991
|
0.78
|
|
287
|
Cytocompatibility of novel tin oxide thin films.
|
J Mater Sci Mater Med
|
2005
|
0.78
|
|
288
|
EPIC: an effective low toxicity regimen for relapsing lymphoma.
|
Br J Cancer
|
1993
|
0.78
|
|
289
|
A standardised order form improved decision-making and documentation of DNR orders.
|
Clin Med
|
2002
|
0.78
|
|
290
|
The bioavailability of oral fludarabine phosphate is unaffected by food.
|
Hematol J
|
2001
|
0.78
|
|
291
|
Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1.
|
Oncogene
|
1997
|
0.78
|
|
292
|
Natural killer cell activity in early human pregnancy.
|
Gynecol Obstet Invest
|
1994
|
0.78
|
|
293
|
Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption.
|
Clin Nephrol
|
1997
|
0.78
|
|
294
|
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
|
Anticancer Drugs
|
1999
|
0.78
|
|
295
|
Mycobacterium vaccae: a study of safety and outcome measures.
|
Respir Med
|
1998
|
0.77
|
|
296
|
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
|
Clin Oncol (R Coll Radiol)
|
2005
|
0.77
|
|
297
|
Pyridoxal 5'-diphospho-5'-adenosine binds at a single site on isolated alpha-subunit from Escherichia coli F1-ATPase and specifically reacts with lysine 201.
|
J Biol Chem
|
1988
|
0.77
|
|
298
|
Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
|
Leuk Lymphoma
|
1994
|
0.77
|
|
299
|
Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours.
|
Br J Surg
|
2012
|
0.77
|
|
300
|
Advanced pancreatic cancer--5 years on.
|
Ann Oncol
|
2002
|
0.77
|
|
301
|
Emerging therapies for rectal cancer.
|
Colorectal Dis
|
2006
|
0.77
|
|
302
|
Combination chemotherapy and colorectal cancer.
|
Semin Oncol
|
2000
|
0.77
|
|
303
|
Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin's lymphoma.
|
Cancer Chemother Pharmacol
|
1985
|
0.77
|
|
304
|
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
|
Br J Cancer
|
1993
|
0.77
|
|
305
|
Safety of raltitrexed.
|
Lancet
|
1999
|
0.76
|
|
306
|
Short duration combination chemotherapy in the treatment of small cell lung cancer.
|
Thorax
|
1986
|
0.76
|
|
307
|
Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits.
|
Eur J Cancer
|
1996
|
0.76
|
|
308
|
The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.
|
Bone Marrow Transplant
|
1998
|
0.76
|
|
309
|
Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.
|
Leuk Lymphoma
|
1992
|
0.76
|
|
310
|
Detecting t(14;18) in paraffin-embedded lymphoma tissue.
|
Lancet
|
1989
|
0.76
|
|
311
|
Adjuvant therapy for colon cancer in the new millenium.
|
Scand J Surg
|
2003
|
0.76
|
|
312
|
Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
|
Eur J Cancer
|
2000
|
0.75
|
|
313
|
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2007
|
0.75
|
|
314
|
A selective policy in follow-up for bowel cancer.
|
Lancet
|
1998
|
0.75
|
|
315
|
Prognostic significance of transient ST segment changes after coronary artery bypass surgery: a long-term (4-10 year) follow up study.
|
Br Heart J
|
1993
|
0.75
|
|
316
|
The effects of capecitabine in Raynaud's disease: a case report.
|
Ann Oncol
|
2005
|
0.75
|
|
317
|
Communicable disease control in London.
|
BMJ
|
1993
|
0.75
|
|
318
|
ECF in gastric cancer.
|
J Clin Oncol
|
2000
|
0.75
|
|
319
|
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
|
Br J Cancer
|
2001
|
0.75
|
|
320
|
Chemotherapy related pulmonary embolus recognized.
|
BMJ
|
1988
|
0.75
|
|
321
|
Survival from cancer of the stomach in England and Wales up to 2001.
|
Br J Cancer
|
2008
|
0.75
|
|
322
|
Pre- and postoperative chemotherapy for resectable gastric adenocarcinoma.
|
Ann R Coll Surg Engl
|
1998
|
0.75
|
|
323
|
Colorectal cancer.
|
Lancet
|
1999
|
0.75
|
|
324
|
Survival after systemic therapy for metastatic colorectal cancer.
|
Lancet
|
1995
|
0.75
|
|
325
|
Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).
|
Br J Cancer
|
2004
|
0.75
|
|
326
|
Repeat administration of high dose melphalan in relapsed myeloma.
|
Br J Cancer
|
1993
|
0.75
|
|
327
|
4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.
|
Steroids
|
1988
|
0.75
|
|
328
|
Adequate number of patients are needed to evaluate adjuvant treatment in gastric cancer.
|
J Clin Oncol
|
1998
|
0.75
|
|
329
|
The organizational question: informatics and information management in the academic health sciences center.
|
Bull Med Libr Assoc
|
1995
|
0.75
|
|
330
|
The 6 day subrenal capsule assay is of no value with primary surgical explants from gastric cancer.
|
Br J Cancer
|
1986
|
0.75
|
|
331
|
Standard chemotherapy for gastric carcinoma: is it a myth?
|
J Clin Oncol
|
2001
|
0.75
|
|
332
|
Adjuvant chemotherapy.
|
Lancet
|
2000
|
0.75
|
|
333
|
Optimising treatment regimens for the management of advanced gastric cancer.
|
Ann Oncol
|
2009
|
0.75
|
|
334
|
Mutant K-ras2 in serum.
|
Gut
|
2003
|
0.75
|
|
335
|
Coronary heart disease, the menopause, and hormone replacement therapy.
|
Br Heart J
|
1994
|
0.75
|
|
336
|
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
|
Br J Cancer
|
2001
|
0.75
|
|
337
|
Chemotherapy of oesophago-gastric cancer.
|
Pathol Oncol Res
|
1998
|
0.75
|
|
338
|
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
|
Br J Cancer
|
2010
|
0.75
|
|
339
|
Endocavitary ablation of atrioventricular conduction.
|
Br Heart J
|
1990
|
0.75
|
|
340
|
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
|
Eur J Cancer
|
1995
|
0.75
|
|
341
|
Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.
|
Ann Oncol
|
1994
|
0.75
|
|
342
|
Expression of protease nexin-II in human dorsal root ganglia. A correlative immunocytochemical and in situ hybridization study.
|
Mol Chem Neuropathol
|
1992
|
0.75
|
|
343
|
Gastrointestinal non-Hodgkin's lymphoma.
|
Baillieres Clin Gastroenterol
|
1990
|
0.75
|
|
344
|
A characteristics protein highly expressed in guinea pig inner ear, defined by monoclonal antibody WH-1.
|
Hear Res
|
1994
|
0.75
|
|
345
|
Haematological toxicity of radiotherapy following high-dose chemotherapy and autologous bone marrow transplantation in patients with recurrent Hodgkin's disease.
|
Eur J Cancer
|
1994
|
0.75
|
|
346
|
Inflammation of solar keratoses following systemic 5-fluorouracil.
|
Br J Dermatol
|
1996
|
0.75
|
|
347
|
Community education as a marketing tool for your hospital.
|
Health Mark Q
|
1986
|
0.75
|
|
348
|
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
|
Ann Oncol
|
2002
|
0.75
|
|
349
|
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
|
Clin Oncol (R Coll Radiol)
|
2003
|
0.75
|
|
350
|
Influence of active recovery on professional rugby union player's ability to harness postactivation potentiation.
|
J Sports Med Phys Fitness
|
2013
|
0.75
|
|
351
|
Where am I? Orientation for fundus photography.
|
J Ophthalmic Nurs Technol
|
1988
|
0.75
|
|
352
|
Current advances in the treatment of gastrointestinal malignancy.
|
Crit Rev Oncol Hematol
|
1993
|
0.75
|
|
353
|
Improving your teaching skills.
|
Nursing
|
1993
|
0.75
|
|
354
|
A pilot study of intraperitoneal cisplatin in the management of gastric cancer.
|
Ann Oncol
|
1994
|
0.75
|
|
355
|
Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.
|
Cancer Chemother Pharmacol
|
1986
|
0.75
|
|
356
|
One-pot synthesis of fluorescent 2,5-dihydro-1,2,3-triazine derivatives from a cascade rearrangement sequence in the reactions of 1,2,3-triazolium-1-aminide 1,3-dipoles with propiolate esters.
|
J Org Chem
|
2006
|
0.75
|
|
357
|
Other imaging in bony metastases.
|
Nucl Med Commun
|
1995
|
0.75
|
|
358
|
A pilot study of cisplatin based combination chemotherapy in gastric cancer.
|
Clin Oncol (R Coll Radiol)
|
1993
|
0.75
|
|
359
|
Evidence for selective sulfhydryl reactivity in cytochalasin A--mediated bacterial inhibitions.
|
Biochem Biophys Res Commun
|
1979
|
0.75
|
|
360
|
Sepsis reduces isoflurane MAC in a normotensive animal model of sepsis.
|
Can J Anaesth
|
1995
|
0.75
|
|
361
|
Experience with intermediate-dose (110-120 mg/m2) epirubicin.
|
Cancer Chemother Pharmacol
|
1989
|
0.75
|
|
362
|
Current therapy and future prospects in lymphoma.
|
Expert Rev Anticancer Ther
|
2001
|
0.75
|
|
363
|
How the tax shelters stand up now: real estate.
|
Dent Manage
|
1973
|
0.75
|
|
364
|
Central venous access resulting in selective failure of ICD defibrillation capacity.
|
Pacing Clin Electrophysiol
|
2001
|
0.75
|
|
365
|
Macular deposits in galactokinase deficiency.
|
Metab Pediatr Syst Ophthalmol (1985)
|
1985
|
0.75
|
|
366
|
Effects of amlodipine versus diltiazem on morning peak in myocardial ischemic activity in angina pectoris.
|
Am J Cardiol
|
1993
|
0.75
|
|
367
|
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial.
|
Invest New Drugs
|
2013
|
0.75
|
|
368
|
Whooping cough in West London.
|
Lancet
|
1983
|
0.75
|
|
369
|
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
|
Eur J Cancer
|
1995
|
0.75
|
|
370
|
A crystallizable form of RIIbeta regulatory domain obtained by limited proteolysis.
|
Acta Crystallogr D Biol Crystallogr
|
2000
|
0.75
|
|
371
|
Chemotherapy improves pulmonary function in a patient with gastric cancer.
|
Br J Clin Pract
|
1986
|
0.75
|
|
372
|
Donor properties of the vanadyl ion: reactions of vanadyl salicylaldimine beta-ketimine and acetylacetonato complexes with groups 14 and 15 Lewis acids.
|
Inorg Chem
|
2002
|
0.75
|
|
373
|
Treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide, adriamycin and cis-platinum.
|
Br J Obstet Gynaecol
|
1984
|
0.75
|
|
374
|
Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.
|
Cancer Chemother Pharmacol
|
1992
|
0.75
|
|
375
|
A comparison of the conversion in vitro of pregnenolone sulphate and pregnenolone to steroid hormones by tissue from a clear cell adenoma of the adrenal gland.
|
J Endocrinol
|
1968
|
0.75
|
|
376
|
Small cell lung cancer: results of a phase II study of 1,2,4 triglycidylurazol.
|
Cancer Chemother Pharmacol
|
1986
|
0.75
|
|
377
|
Intra-abdominal panniculitis can mimic recurrent stomach carcinoma.
|
Clin Oncol (R Coll Radiol)
|
1992
|
0.75
|
|
378
|
Oesophageal cancer: preoperative chemotherapy.
|
Ann Oncol
|
2004
|
0.75
|
|
379
|
Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna.
|
Cancer Treat Rev
|
1983
|
0.75
|
|
380
|
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
|
Bone Marrow Transplant
|
1998
|
0.75
|
|
381
|
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
|
J Infus Chemother
|
1996
|
0.75
|
|
382
|
Combined therapy for middle ear rhabdomyosarcoma.
|
Am J Dis Child
|
1972
|
0.75
|
|
383
|
On the Relation of Fungi to Disease.
|
Ind Med Gaz
|
1870
|
0.75
|
|
384
|
Nursing interventions: independent or not?
|
Nurs Manage
|
1988
|
0.75
|
|
385
|
Local recurrence of a primary pancreatic lymphoma 18 years after complete remission.
|
Hematol Oncol
|
1998
|
0.75
|
|
386
|
Progress in the multidisciplinary treatment of gastrointestinal cancers, impact on clinical practice: peri-operative management of gastro-esophageal cancer.
|
Ann Oncol
|
2008
|
0.75
|
|
387
|
Dental health of mentally and physically handicapped children.
|
Community Dent Health
|
1987
|
0.75
|
|
388
|
Should induction chemotherapy be considered for all patients with gastric cancer?
|
Eur J Surg Oncol
|
1994
|
0.75
|
|
389
|
Adult respiratory distress syndrome in a child with acute epiglottitis.
|
Crit Care Med
|
1986
|
0.75
|
|
390
|
Telerehabilitation services using web-based telecommunication.
|
Stud Health Technol Inform
|
2000
|
0.75
|
|
391
|
CT evaluation of the resectability of gastric cancer postchemotherapy.
|
Abdom Imaging
|
1996
|
0.75
|
|
392
|
A new tricyclic ring and a nitrogen-sulfur analogue of the tri-pentagon bowl. Substituted 5,6,7,7a-tetrahydropyrrolo[2,1-b]-1,3,4-thiadiazole- endo-6,7-dicarboxyimides.
|
Chem Commun (Camb)
|
2001
|
0.75
|
|
393
|
The role of chemotherapy for metastatic gastric cancer.
|
J Infus Chemother
|
1995
|
0.75
|
|
394
|
Management of vomiting associated with cytotoxic therapy.
|
Br J Hosp Med
|
1991
|
0.75
|
|
395
|
The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
|
Semin Oncol
|
1985
|
0.75
|
|
396
|
Staff nurses rate clinical ladder program.
|
Am Nurse
|
1988
|
0.75
|
|
397
|
Doctors on the move.
|
J R Coll Gen Pract Occas Pap
|
1979
|
0.75
|
|
398
|
Government directives and changes: the potential impact on clinical practice.
|
J R Coll Physicians Lond
|
2000
|
0.75
|
|
399
|
Preparation and Crystal Structure of a Platinum(II) Complex of [CH(2)N(CH(2)COOH)CH(2)CONH(2)](2), the Hydrolysis Product of an Anti-Tumour Bis(3,5-Dioxopiperazin-1-YL)Alkane.
|
Met Based Drugs
|
1994
|
0.75
|
|
400
|
The management of colorectal cancer: chemotherapy.
|
Crit Rev Oncol Hematol
|
1999
|
0.75
|
|
401
|
The role of systemic therapy for localised gastric cancer.
|
Ann Oncol
|
2006
|
0.75
|
|
402
|
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
|
Clin Oncol (R Coll Radiol)
|
2003
|
0.75
|
|
403
|
TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage.
|
Med Oncol Tumor Pharmacother
|
1986
|
0.75
|
|
404
|
CT detection of hydronephrosis in resected colorectal cancer: a predictor of recurrent disease.
|
Clin Radiol
|
2003
|
0.75
|
|
405
|
A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
|
Eur J Cancer Clin Oncol
|
1986
|
0.75
|
|
406
|
Plasma carbon dioxide as measured colorimetrically and with an ion-selective electrode (RA-1000).
|
Clin Chem
|
1986
|
0.75
|
|
407
|
Chemotherapy of metastatic bowel cancer.
|
Br J Hosp Med
|
1996
|
0.75
|
|
408
|
Exercise proteinuria.
|
Med Sci Sports
|
1970
|
0.75
|
|
409
|
Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro.
|
Leukemia
|
1991
|
0.75
|
|
410
|
CHILD syndrome: clinical picture and diagnostic procedures.
|
J Eur Acad Dermatol Venereol
|
2007
|
0.75
|
|
411
|
Application of scanning force microscopy to chromosome analysis.
|
Cancer Genet Cytogenet
|
1994
|
0.75
|
|
412
|
The management of colorectal cancer.
|
Crit Rev Oncol Hematol
|
1999
|
0.75
|
|
413
|
Expansion of the organ donor pool by the reuse of a previously transplanted kidney--is this ethically and scientifically valid?
|
Transplant Proc
|
2002
|
0.75
|
|
414
|
Public health in London.
|
BMJ
|
1988
|
0.75
|